NEW YORK — Sienna Cancer Diagnostics said on Wednesday that it has signed an exclusive distribution agreement for its hTERT test for bladder cancer in New Zealand with Scientle Innovations.
Sienna's in vitro diagnostic is designed to detect the hTERT component of telomerase, a biomarker that aids in the diagnosis of bladder cancer alongside standard urine cytology testing.
Under the terms of the deal, Christchurch-based Scientle will exclusively distribute the test to pathology labs in New Zealand. Melbourne, Australia-based Sienna will provide Scientle with regulatory support, as well as sales, marketing, and technical training. When COVID-19-related travel restrictions lift, the companies will also work together to establish hTERT testing in New Zealand reference labs to support adoption of Sienna's product.
Additional terms were not disclosed.
With the Scientle arrangement, Sienna said it has signed 10 distribution agreements for its hTERT test including one with Immuno Diagnostic covering Finland earlier this year.
Last month, Bard1 Life Sciences signed an agreement to acquire Sienna for roughly A$23.7 million ($15.3 million) in stock. That transaction is expected to close midyear.